Top

Published in:

01-04-2022 | Metastasis | Review Article

Therapy-induced bone changes in oncology imaging with ¹⁸F-sodium fluoride (NaF) PET–CT

Authors: Najeeb Ahmed, Alyaa Sadeq, Fahad Marafi, Gopinath Gnanasegaran, Sharjeel Usmani

Published in: Annals of Nuclear Medicine | Issue 4/2022

Abstract

¹⁸F-Sodium fluoride (¹⁸F-NaF) is a PET tracer that is mostly used in the evaluation of bone metastasis in oncology cases. Recently, ¹⁸F-NaF PET/CT is gaining wide popularity owing to its higher sensitivity over the other conventional bone tracer with higher and rapid single-pass extraction, negligible plasma protein binding, rapid blood, and renal clearance. In the era of constant evolution of cancer therapy regimens, considerable bone health impact is seen in the form of avascular necrosis, insufficiency fractures, among others. A significant number of these therapy-induced changes show high bone turnover and thereby ¹⁸F-NaF accumulation, mimicking metastatic lesions. This article summarizes and illustrates the pattern and morphological features of ¹⁸F-NaF PET/CT findings in these changes in the context of clinical and therapeutic history.

Czernin J, Satyamurthy N, Schiepers C. Molecular mechanisms of bone 18F-NaF deposition. J Nucl Med. 2010;51:1826–9.PubMed

Laverick S, Bounds G, Wong WL. [18F]-Fluoride positron emission tomography for imaging condylar hyperplasia. Br J Oral Maxillofac Surg. 2009;47:196–9.PubMed

Sachpekidis C, Hillengass J, Goldschmidt H, et al. Quantitative analysis of 18F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myeloma. Am J Nucl Med Mol Imaging. 2017;7:148–56.PubMedPubMedCentral

Frost ML, Blake GM, Cook GJ, et al. Differences in regional bone perfusion and turnover between lumbar spine and distal humerus: 18F-fluoride PET study of treatment-naive and treated postmenopausal women. Bone. 2009;45:942–8.PubMed

Blake GM, Park-Holohan SJ, Cook GJ, et al. Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. Semin Nucl Med. 2001;31:28–49.PubMed

Beheshti M, Mottaghy FM, Payche F, et al. 18 F-NaF PET/CT: EANM procedure guidelines for bone imaging. Eur J Nucl Med Mol Imaging. 2015;42:1767–77.PubMed

Segall G, Delbeke D, Stabin MG, et al. SNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0. J Nucl Med. 2010;51:1813–20.PubMed

Usmani S, Ahmed N, Gnanasegaran G, Musbah A, Al Kandari F, Van den Wyngaert T. 18F-Sodium Fluoride (NaF) PET/CT in obese patients on LYSO PET/CT system: patient dosimetry, optimization of injected activity and acquisition time. J Nucl Med Technol. 2020. https://doi.org/10.2967/jnmt.120.258137.CrossRefPubMed

D’Oronzo S, Stucci S, Tucci M, Silvestris F. Cancer treatment-induced bone loss (CTIBL): pathogenesis and clinical implications. Cancer Treat Rev. 2015;41(9):798–808.PubMed

10.

Kwak JJ, Tirumani SH, Van den Abbeele AD, et al. Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. Radiographics. 2015;35:424–37.PubMed

11.

Bronstein Y, Ng CS, Hwu P, et al. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol. 2011;197:W992–1000.PubMed

12.

Wissing MD. Chemotherapy- and irradiation-induced bone loss in adults with solid tumors. Curr Osteoporos Rep. 2015;13:140–5.PubMedPubMedCentral

13.

Haworth AE, Webb J. Skeletal complications of bisphosphonate use: what the radiologist should know. Br J Radiol. 2012;85:1333–42.PubMedPubMedCentral

14.

Nicolatou-Galitis O, Schiødt M, Mendes RA, et al. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019;127:117–35.PubMed

15.

Kim Y, Lee HY, Yoon HJ, et al. Utility of 18F-fluorodeoxy glucose and 18F-sodium fluoride positron emission tomography/computed tomography in the diagnosis of medication-related osteonecrosis of the jaw: a preclinical study in a rat model. J Craniomaxillofac Surg. 2016;44:357–63.PubMed

16.

Wilde F, Steinhoff K, Frerich B, et al. Positron-emission tomography imaging in the diagnosis of bisphosphonate-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;107:412–9.PubMed

17.

Raje N, Woo SB, Hande K, et al. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res. 2008;14:2387–95.PubMed

18.

Tile L, Cheung AM. Atypical femur fractures: current understanding and approach to management. Ther Adv Musculoskelet Dis. 2020. https://doi.org/10.1177/1759720X20916983.CrossRefPubMedPubMedCentral

19.

Laarschot DM, Somford MP, Jager A, et al. “Atypical” atypical femur fractures and use of bisphosphonates. Clin Cases Miner Bone Metab. 2016;13:204–8.PubMed

20.

Roca-Ayats N, Balcells S, Garcia-Giralt N, et al. GGPS1 mutation and atypical femoral fractures with bisphosphonates. N Engl J Med. 2017;376:1794–5.PubMed

21.

Spyridonidis TJ, Mousafiris KV, Rapti EK, et al. Bone scintigraphy depicts bilateral atypical femoral stress fractures with metachronous presentation, long before a complete fracture occurs. Hell J Nucl Med. 2014;17:54–7.PubMed

22.

D’Oronzo S, Stucci S, Tucci M, Silvestris F. Cancer treatment-induced bone loss (CTIBL): pathogenesis and clinical implications. Cancer Treat Rev. 2015;41:798–808.PubMed

23.

Brufsky AM. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives. Oncologist. 2008;13:187–95.PubMed

24.

Bjarnason NH, Hitz M, Jorgensen NR, et al. Adverse bone effects during pharmacological breast cancer therapy. Acta Oncol. 2008;47:747–54.PubMed

25.

Agrawal K, Tripathy SK, Sen RK, et al. Nuclear medicine imaging in osteonecrosis of hip: old and current concepts. World J Orthop. 2017;8:747–53.PubMedPubMedCentral

26.

Dasa V, Adbel-Nabi H, Anders MJ, Mihalko WM. F-18 fluoride positron emission tomography of the hip for osteonecrosis. Clin Orthop Relat Res. 2008;466(5):1081–6.PubMedPubMedCentral

27.

Gayana S, Bhattacharya A, Sen RK, Singh P, Prakash M, Mittal BR. F-18 fluoride positron emission tomography/computed tomography in the diagnosis of avascular necrosis of the femoral head: comparison with magnetic resonance imaging. Indian J Nucl Med. 2016;31:3–8.PubMedPubMedCentral

28.

Huh SJ, Kim B, Kang MK, et al. Pelvic insufficiency fracture after pelvic irradiation in uterine cervix cancer. Gynecol Oncol. 2002;86:264–8.PubMed

29.

Chung YK, Lee YK, Yoon BH, Suh DH, Koo KH. Pelvic insufficiency fractures in cervical cancer after radiation therapy: a meta-analysis and review. In Vivo. 2021;35:1109–15.PubMedPubMedCentral

30.

Peh WC, Khong PL, Yin Y, et al. Imaging of pelvic insufficiency fractures. Radiographics. 1996;16:335–48.PubMed

31.

Lapina O, Tiškevičius S. Sacral insufficiency fracture after pelvic radiotherapy: a diagnostic challenge for a radiologist. Medicina (Kaunas). 2014;50:249–54.

32.

Soares PBF, Soares CJ, Limirio PHJO, et al. Effect of ionizing radiation after-therapy interval on bone: histomorphometric and biomechanical characteristics. Clin Oral Investig. 2019;23:2785–93.PubMed

33.

Israel O, Gorenberg M, Frenkel A, et al. Local and systemic effects of radiation on bone metabolism measured by quantitative SPECT. J Nucl Med. 1992;33:1774–80.PubMed

34.

Lloyd S, Decker RH, Evans SB. Bone scan findings of chest wall pain syndrome after stereotactic body radiation therapy: implications for the pathophysiology of the syndrome. J Thorac Dis. 2013;5:E41–4.PubMedPubMedCentral

35.

Park W, Huh SJ, Yang JH, et al. The implication of hot spots on bone scans within the irradiated field of breast cancer patients treated with mastectomy followed by radiotherapy. Ann Nucl Med. 2008;22:685–91.PubMed

36.

Benfaremo D, Manfredi L, Luchetti MM, et al. Musculoskeletal and rheumatic diseases induced by immune checkpoint inhibitors: a review of the literature. Curr Drug Saf. 2018;13:150–64.PubMedPubMedCentral

37.

Naidoo J, Cappelli LC, Forde PM, et al. Inflammatory arthritis: a newly recognized adverse event of immune checkpoint blockade. Oncologist. 2017;22:627–30.PubMedPubMedCentral

38.

Smith MH, Bass AR. Arthritis after cancer immunotherapy: symptom duration and treatment response. Arthritis Care Res (Hoboken). 2019;71:362–6.

39.

Belkhir R, Burel SL, Dunogeant L, et al. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis. 2017;76:1747–50.PubMed

40.

Nobashi T, Mittra E. PD-1 blockade–induced inflammatory arthritis. Radiology. 2018;289:616.PubMed

41.

Jiang W, Rixiati Y, Zhao B, Li Y, Tang C, Liu J. Incidence, prevalence, and outcomes of systemic malignancy with bone metastases. J Orthop Surg (Hong Kong). 2020;28:2309499020915989.

42.

Vaz S, Usmani S, Gnanasegaran G, et al. Molecular imaging of bone metastases using bone targeted tracers. Q J Nucl Med Mol Imaging. 2019;63:112–28.PubMed

43.

Hillner BE, Siegel BA, Hanna L, et al. Impact of 18F-fluoride PET in patients with known prostate cancer: initial results from the National Oncologic PET Registry. J Nucl Med. 2014;55:574–81.PubMed

44.

Drubach LA. Clinical utility of 18F NaF PET/CT in benign and malignant disorders. Pet Clin. 2012;7:293–301.PubMed

45.

Usmani S, Ahmed N, Muzaffar S, et al. Spectrum of false positive 18F-sodium fluoride (NaF) bone PET/CT findings in oncology imaging; a narrative pictorial review of cases from a single institution. Hell J Nucl Med. 2020;23:67–75.PubMed

Title: Therapy-induced bone changes in oncology imaging with 18F-sodium fluoride (NaF) PET–CT
Authors: Najeeb Ahmed
Alyaa Sadeq
Fahad Marafi
Gopinath Gnanasegaran
Sharjeel Usmani
Publication date: 01-04-2022
Publisher: Springer Singapore
Keywords: Metastasis
Bisphosphonate
Osteonecrosis
Published in: Annals of Nuclear Medicine / Issue 4/2022
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-022-01730-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Therapy-induced bone changes in oncology imaging with ¹⁸F-sodium fluoride (NaF) PET–CT

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2022

[18F]FDG uptake in axillary lymph nodes and deltoid muscle after COVID-19 mRNA vaccination: a cohort study to determine incidence and contributing factors using a multivariate analysis

Predictive value of multiple metabolic and heterogeneity parameters of 18F-FDG PET/CT for EGFR mutations in non-small cell lung cancer

Conversion from dose length product to effective dose for the CT component of whole-body PET/CT

Deep learning for image classification in dedicated breast positron emission tomography (dbPET)

Initial evaluation of a new maximum-likelihood attenuation correction factor-based attenuation correction for time-of-flight brain PET

Correlation between noise pareidolia test scores for visual hallucinations and regional cerebral blood flow in dementia with Lewy bodies